Amgen rebounds after denying bone safety concerns linked to obesity drug
Amgen (AMGN) stock spiked after the company ruled out out bone density concerns linked to obesity drug MariTide, following a ...
Amgen sees no bone safety concerns around experimental obesity drug
Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a ...
Amgen slips as Cantor cites safety concerns linked to obesity candidate
Amgen (AMGN) stock falls as Cantor Fitzgerald raises safety concerns over bone mineral density loss linked to obesity ...
Amgen stock falls as analysts mull over weight loss drug's bone density data
Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...
Benzinga.com16h
Jim Cramer Says Eli Lilly's 'Pathetic' Stock Performance Could Get A Breather If Amgen Has Hidden Bone Risk Data After 7% Stock Drop
Amgen Inc.‘s AMGN stock dropped over 7% on Tuesday following revelations about bone density loss in early trials of its ...
pharmaphorum5d
Amgen to push latecomer obesity drug into midstage testing
Amgen will now move ahead with a phase 2 programme for AMG 133, as it tries to enter a weight-loss category that has been transformed by the approval of Novo Nordisk’s once-weekly GLP-1 agonist ...
Space.com1d
Space pictures! See our space image of the day
Citizen scientists working with the raw image data, which is available to the public online, increased the contrast of the images captured in visible light to emphasize the planet's striking color ...
pharmaphorum4d
Amgen's Soliris biosimilar clears phase 3, but won't launch until 2025
Amgen has reported positive phase 3 results with its biosimilar version of AstraZeneca/Alexion's blockbuster rare disease drug Soliris, setting up a regulatory filing with the FDA.